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1) Presence of halo sign is associated with ischaemic symptoms of giant cell arteritis  
2) Physical examination findings are related to the presence of ipsilateral temporal 
artery halo  
3) Temporal artery halo thickness consistently decreases with glucocorticoids in the 
first 7-days of treatment 
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Objectives: To compare the ultrasound characteristics with clinical features, final 
diagnosis and outcome; and to evaluate the halo size following glucocorticoid (GC) 
treatment in patients with newly diagnosed giant cell arteritis (GCA). 
Methods: Patients with suspected GCA, recruited from an international cohort, had 
an ultrasound of temporal (TA) and axillary (AX) arteries performed within 7-days of 
commencing GCs. We compared differences in clinical features at disease 
presentation, after 2-weeks and after 6-months, according to the presence or absence 
of halo sign. We undertook a cross-sectional analysis of the differences in halo 
thickness using Pearson's correlation coefficient (r) and Analysis of Variance (ANOVA). 
Results: A total of 345 patients with 6-months follow-up data were included; 226 
(65.5%) had a diagnosis of GCA. Jaw claudication and visual symptoms were more 
frequent in patients with halo sign (p=0.018 and p=0.003, respectively). Physical 
examination abnormalities were significantly associated with the presence of 
ipsilateral halo (p<0.05). Stenosis or occlusion on ultrasound failed to contribute to 
the diagnosis of GCA. During 7 days of GC treatment, there was a consistent reduction 
in halo size in the TA (maximum halo size per patient: r=-0.30, p=0.001; and all halos 
r=-0.23, p<0.001), but not in the AX (p>0.05). However, the presence of halo at 
baseline failed to predict future ischaemic events occurring during follow-up.  
Conclusions: In newly diagnosed GCA, TA halo is associated with the presence of 
ischaemic features and its size decreases following GC treatment, supporting its early 






Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis in 
patients aged > 50 years, affecting large and medium-sized arteries, in particular the 
aorta and its main branches [1,2]. Irreversible visual loss secondary to ischaemic optic 
neuropathy is one of the most serious complications of the disease [3]. Therefore, 
early diagnosis should be achieved and glucocorticoid (GC) treatment initiated as soon 
as possible to avoid ischaemic complications. However, GCA is a diagnostic challenge. 
The history, typical clinical findings and elevation of acute phase reactants are usually 
sufficient to lead to a suspicion of GCA but are not enough to give diagnostic certainty 
[4]. Temporal artery biopsy (TAB) has been considered the gold-standard for the 
diagnosis of GCA because of its high specificity; however, TAB has various limitations 
[5–8], particularly its low sensitivity for diagnosis (around 40% [9]). 
During the last decade, high-resolution ultrasound has attracted considerable interest 
as a non-invasive diagnostic tool for patients with suspected GCA [10–14]. The 
presence of a non-compressible, hypoechoic, most commonly concentric arterial wall 
thickening, known as the ‘halo sign’, is highly specific for the diagnosis of GCA [15,16] 
and it has already been proposed as part of a diagnostic algorithm for this disease 
[4,17]. In addition, many studies have suggested cut-off values for the intima-media 
thickness (IMT) to define positive halo sign [18–23]. Schäfer et al. compared patients 
with controls in a prospective study assessing the IMT of arteries commonly involved 
in GCA: the cut-off values for the common superficial temporal arteries, the frontal 
and parietal branches, and the axillary arteries with the best performance 
characteristics to diagnose GCA were 0.42, 0.34, 0.29, and 1.0 mm, respectively [24]. 
In addition, the presence of bilateral halo sign has been reported to increase the 
specificity for GCA diagnosis by up to 100% [25]. Stenoses and occlusions, although 
less specific for GCA, may also be present in patients with GCA [26]. 
Ultrasound may also be useful to assess inflammatory activity in response to 
treatment [17,19,25,27,28]. De Miguel and colleagues have reported an association 
between halo disappearance and reduction of inflammatory markers. Moreover, a 
larger number of temporal artery branches affected by the disease before treatment 
initiation has been associated with increased values of CRP and ESR and slower 
resolution of the halo sign [19]. In addition, patients with large-vessel involvement 
seem to be less likely to have visual impairment [29,30]; however, abnormalities on 
temporal artery ultrasound do not appear to correlate with eye complications [30]. 
The halo sign of the temporal arteries has been reported to disappear after a mean of 
2-10 weeks following initiation of GC treatment [15,18,19,25], but persists for much 
longer in the axillary arteries [31]. However, early halo sign variation with treatment 
has yet to be assessed. 
The role of ultrasound compared to TAB in the diagnosis of GCA (TABUL) study [9] 
evaluated the diagnostic accuracy and the cost-effectiveness of ultrasound in a 
prospective multicentre cohort study that included 430 patients with suspected GCA. 
All patients underwent both ultrasound of the temporal and axillary arteries and TAB 
in the first 7-days of commencing high-doses of GCs (>20 mg of prednisolone or 
equivalent per day) and were assessed at three time points (baseline, 2-weeks, and 6-
months) for clinical features of the disease, adverse events and diagnostic certainty.  
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The present study is a sub-analysis of the TABUL cohort with the specific aim of 
assessing the halo sign variation with GC treatment within a 7-day period for the 
temporal and axillary arteries, and to compare the halo sign characteristics (presence, 
size, anatomical distribution and number of sites affected) with ischaemic features of 




Patients and data collection: 
A total of 430 patients were originally recruited at baseline into the TABUL study 
(ClinicalTrials.gov Identifier: NCT00974883) from 20 centres in 5 different countries 
(United Kingdom, Ireland, Norway, Germany and Portugal) from June 2010 to 
December 2013; 396 patients were assessed at 2-weeks; and 345 patients at 6-
months. TAB and ultrasound were completed before the 2-weeks assessment. For 
diagnostic purposes, TAB results were provided to the clinician before the 2-week 
assessment, but ultrasound results only before the 6-months visit. Therefore, only 
patients with a complete 6-months assessment, in which the clinician decided on final 
diagnosis with full knowledge of the data, were used as the cohort for this study. The 
data from the TABUL study was collected in the PROSPECT database (Clinical Trials 
Unit, Sheffield University). Ethical approval was obtained for the study (REC No. 09/ 
H0505/132) and patients signed informed consent prior to inclusion in the study. 
 
Technical ultrasound specifications: 
In the TABUL study, a specific scanning protocol was used to ensure a systematic 
examination of 10 arterial territories of interest: bilateral common superficial 
temporal arteries (TA), parietal branches, proximal and distal segments of the frontal 
branches, and bilateral distal segment of the axillary (AX) arteries [32]. The 
sonographers were required to report the presence or absence of any ultrasound 
abnormality including halo sign, stenosis, occlusion, and atherosclerosis for each of 
the TA segments and AX arteries. If the presence of halo sign was reported, 
investigators were additionally asked to detail its maximum thickness. To support the 
findings, video and static images, in both longitudinal and transverse planes, were 
acquired and reviewed by a panel of ultrasound experts.  
Ultrasound machines with linear probes were used to perform all scans.  
Sonographers were instructed to use the following settings: vascular pre-set; focus 
positioned 5 mm below skin surface for TA; grey scale frequency ≥10 MHz; colour 
Doppler with frequency ≥6 MHz; pulse repetition frequency at approximately 2–3 kHz; 
colour box with angle correction for longitudinal scans; and gain adjusted to fill only 
the lumen. 
As part of the TABUL study, all scans were performed at one single time point around 
the onset of disease. All sonographers undertook a training program that consisted of 
an online review of 20 ultrasound images, and the correct scanning of a patient with 
active GCA plus scanning of 10 healthy controls, which was independently assessed by 





Data were summarized by mean  standard deviation (SD) for continuous variables, 
and percentages and frequencies for categorical variables. Differences in clinical 
features between patients with the presence or absence of the halo sign at disease 
presentation, 2-weeks and 6-months of follow-up were compared using Student's t-
test and Mann-Whitney non-parametric U test for continuous variables, and Chi-
square test for categorical variables. Shapiro-Wilk test was used to assess normality 
of the continuous variables analysed. Logistic regression was used to determine the 
association between the presence of temporal artery halo and physical examination 
abnormalities of the ipsilateral side, and presence of ultrasound abnormalities and 
final diagnosis of GCA. A cross-sectional analysis of the halo size was performed to 
determine the relationship of the halo size with days of GC treatment using Pearson 
correlation coefficient (r). In addition, analysis of variance (ANOVA) was applied to 
compare the halo size on different days. In all the analyses, the cut-off of p<0.05 was 
adopted for defining statistical significance and confidence intervals (CIs) were 
calculated at 95% level. Given the exploratory nature of the analyses, no adjustment 
was made for multiple testing. Statistical analysis was performed using Statistical 




1) Patient characteristics at disease presentation and presence of halo sign 
A total of 345 patients with complete 6-months data were evaluated; 243 (70.4%) 
females, mean age 70.2±9.4 years. After disclosure of pathology and ultrasonography 
features at 6-months, 226 (65.5%) patients were diagnosed with GCA by the treating 
physician; 158 (69.9%) females, mean age 72.0±8.2 years. 
At disease presentation, the most frequently reported symptoms for patients with 
GCA were localised pain in the head (85.4%), constitutional symptoms (77.9%), 
generalised scalp tenderness (59.3%), and jaw claudication (52.2%) (Supplementary 
Graphic 1). At least one cranial feature (localized headache, scalp tenderness, 
jaw/tongue claudication, or visual symptoms) was present in 220 (97.3%) patients. 
Mean ESR was 53.8±33.3 mm/hr and mean CRP was 55.8±59.8 mg/L. In 214 cases, 
results of TAB were available: 47.2% compatible with vasculitis. In 121 (53.5%) 
patients, ultrasound of the temporal±axillary arteries showed the presence of a halo 
sign.  
Table 1 shows the difference in disease characteristics for patients with a diagnosis of 
GCA and the presence or absence of the halo sign on ultrasound. Patients with halo 
were older (73.1±8.2 vs. 70.8±8.2; p=0.036) with a lower percentage of females 
(66.1% vs. 74.3%; p=0.018); they had a higher percentage of positive TABs (60.3% vs. 
31.6%); more jaw claudication (59.5% vs. 43.8%; p=0.018) and visual symptoms (47.9 
% vs. 28.6%; p=0.003) and higher levels of mean CRP (63.7±58.1 vs. 46.5±59.8; 
p=0.002) at disease presentation. 
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Table 1: Comparison between patients with a diagnosis of GCA with halo vs. no halo 
  
Presence of halo 
on ultrasound 
(n= 121) 





Age (years); mean (SD) 73.1±8.2 70.8±8.2 0.036 
Female sex; n (%) 80 (66.1) 78 (74.3) 0.018 
Diagnostic tests 
Positive TAB (214 results available); n (%) 70 (60.3) 31 (31.6) <0.001 
ESR at baseline (mm/hr); mean (SD) 55.96±31.31 51.24±35.33 0.215 
CRP at baseline (mg/L); mean (SD) 63.72±58.1 46.52±59.83 0.002 
Disease symptoms at presentation, n (%) 
Constitutional symptoms (any) 97 (80.2) 79 (75.2%) 0.373 
Fatigue  76 (62.8) 68 (64.8) 0.761 
Anorexia 53 (43.8) 38 (36.2) 0.245 
Fever or night sweats 52 (43.0) 32 (30.5) 0.052 
PMR features (any) 38 (31.4) 46 (43.8) 0.054 
Bilateral shoulder pain 34 (28.1) 37 (35.2) 0.249 
Early morning stiffness 22 (18.2) 21 (20.0) 0.728 
Bilateral hip stiffness 16 (13.2) 25 (23.8) 0.039 
Localised pain in the head 99 (81.8) 94 (89.5) 0.102 
Generalised scalp tenderness 68 (56.2) 66 (62.9) 0.310 
Jaw claudication 72 (59.5) 46(43.8) 0.018 
Tongue claudication 10 (8.3) 3 (2.9) 0.082 
Visual symptoms (any) 58 (47.9) 30 (28.6) 0.003 
Reduced or lost vision 49 (40.5) 24 (22.9) 0.005 
Double vision 12 (9.9) 5 (4.8) 0.143 
Amaurosis fugax 4 (3.3) 4 (3.8) 0.838 
Stroke (assessed in 220 patients) 0 (0) 2 (2.0) 0.123 
 
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PMR: polymyalgia rheumatica; SD: standard 
deviation; TAB: temporal artery biopsy 
 
*Pearson's Chi-squared test, student's independent t-test or the Mann-Whitney U test 
In bold the statistically significant values (p < 0.05)  
 
 
An abnormal examination of the temporal artery (TA), including reduced or absent 
pulse and tenderness or thickness of the artery, was found in 154/225 (68%) of 
patients with GCA who had this assessment reported: 108 on right TA and 104 on the 
left TA. Regarding visual examination, which included assessment for presence of 
anterior ischaemic optic neuropathy (AION), posterior ischaemic optic neuropathy 
(PION), relative afferent pupillary defect and III/IV/VI nerve palsy, in 22/190 (11.6%) 
patients, pathological findings were reported: 10 in the right eye and 14 in the left eye 
(Supplementary Graphic 1). 
One hundred and twelve of 121 (92.6%) patients had a halo sign reported in the TA 
(91/112 on the right and 86/112 on the left), and 33/121 (27.2%) patients in the AX 
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(23/33 on the right and 25/33 on the left). The presence of a right TA halo was 
associated with pathological findings on physical examination of the ipsilateral side; 
these patients were more likely to present with at least one abnormality on physical 
examination of the right TA (OR 2.2, 95% CI:1.3-3.7), particularly thickened artery and 
change in pulse character (OR 2.4, 95% CI:1.3-4.5, and OR 2.2, 95% CI:1.1-4.2; 
respectively). The same was true for the presence of left TA halo; these patients were 
more likely to have thickened TA on the left side (OR 2.2, 95% CI:1.2-4.1) and left sided 
visual disturbances (OR 4.6, 95% CI:1.4-15.4), in particular AION and relative afferent 
pupillary defect (OR 6.4, 95% CI:1.3-32.3, and OR 10.9, 95% CI:1.2-95.5; respectively) 
(Table 2).  
 
 
Table 2: Association between the presence of halo and physical examination 
abnormalities of the ipsilateral side 
 
 Ipsilateral TA abnormal examination, OR (95% CI) Ipsilateral visual disturbances, OR (95% CI) 
Any1 Thickened Tender Reduced or 
absent pulse 



































*p<0.05; AION: anterior ischaemic optic neuropathy, CI: confidence interval; OR: odds ratio, TA: temporal artery 
 
 
1 - Any TA abnormality on examination: tenderness or thickness of the artery or reduced or absent pulse 
2 - Any visual disturbances on examination: anterior ischaemic optic neuropathy, posterior ischaemic optic neuropathy, relative afferent pupillary 




2) Association between ultrasound findings and final diagnosis of GCA 
Halo sign was reported in 152/345 patients. Out of the 10 artery segments evaluated 
by ultrasound for presence of halo, there were 40 (26.3%) cases involving only 1 
segment, 38 (25.0%) involving 2 segments, 16 (10.5%) involving 3 segments, 18 
(11.8%) involving 4 segments, 5 (3.3%) involving 5 segments, 9 (5.9%) involving 6 
segments, 9 (5.9%) involving 7 segments, 14 (9.2%) involving 8 segments, and 3 (2.0%) 
in which all 10 segments were involved. Amongst patients who had a halo sign 
reported, 144/152 (94.7%) had TA involvement, 40/152 (26.3%) axillary involvement, 
79/152 (52.0%) had bilateral TA involvement, and 17/152 (11.2%) bilateral AX 
involvement. Mean halo thickness of the TA was 0.67±0.35 mm and of the AX 
1.31±0.96 mm.  
The presence of halo was found in 121/226 (53.5%) patients with a diagnosis of GCA 
and 31/119 (26.1%) of patients without GCA (p<0.001). However, when the cut-off 
values for intima-media thickness (IMT) of TA and AX, defined by Schafer et al., were 
applied, the number of patients with halo without a diagnosis of GCA reduced to 
19/119 (16%); there was also a reduction in the number of patients with halo and GCA 
to 107/224 (47.8%) (Supplementary Table 1). In addition, with this adjustment based 
on the IMT cut-off measurements, the OR for GCA diagnosis increased from 3.3 (95% 
CI:2.0-5.3) to 4.6 (95% CI:2.7-8.1) (Table 3).  
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Table 3: Different ultrasound findings as potential risk factors for final diagnosis of GCA 
 
The presence of halo was found in 121/226 (53.5%) patients with a diagnosis of GCA 
and 31/119 (26.1%) of patients without GCA (p<0.001). However, when the cut-off 
 Diagnosis of GCA at 6 months 
 OR  95% CI p-value 
Ultrasound findings 
Presence of halo sign (TA or AX) 3.3 2.0-5.3 <0.001 
TA halo  3.0 1.9-4.9 <0.001 
AX halo 3.3 1.4-8.2 0.009 
Presence of stenosis (TA or AX) 1.2 0.5-3.3 0.665 
TA stenosis 1.0 0.4-2.4 0.940 
AX stenosis 2.0 0.2-18.9 0.546 
Presence of occlusion (TA or AX) 2.3 0.7-7.0 0.151 
TA occlusion 2.2 0.7-6.7 0.180 
Presence of arteriosclerosis (TA or AX) 1.2 0.5-2.6 0.583 
TA arteriosclerosis 1.4 0.6-3.1 0.457 
AX arteriosclerosis 0.7 0.2-3.1 0.666 
Halo general characteristics 
Halo sign with adjusted IMT cut-offs (TA or AX) * 4.6 2.7-8.1 <0.001 
TA halo with adjusted IMT cut-offs * 4.7 2.6-8.4 <0.001 
AX halo with adjusted IMT cut-offs * 4.0 1.2-13.6 0.028 
Bilateral halo (TA or AX) 4.2 2.2-8.1 <0.001 
Bilateral TA halo 3.8 1.9-7.3 <0.001 
Bilateral AX halo 4.2 2.2-8.1 0.061 
TA halo without AX halo 2.4 1.4-3.9 0.001 
TA halo with AX halo 3.1 1.2-8.3 0.024 
Number of arterial segments with the presence of halo 
≥ 1 arterial segments 3.3 2.0-5.3 <0.001 
≥ 2 arterial segments 3.7 2.1-6.4 <0.001 
≥ 3 arterial segments 6.7 3.0-15.2 <0.001 
≥ 4 arterial segments 9.0 3.2-25.6 <0.001 
≥ 5 arterial segments 7.6 2.3-25.1 <0.001 
≥ 6 arterial segments 10.0 2.4-42.5 0.002 
≥ 7 arterial segments 14.7 2.0-109.7 0.009 
Halo thickness 
Maximum TA halo thickness 16.6 3.8-72.5 <0.001 
Mean TA halo thickness 14.5 4.6-45.8 <0.001 
Maximum AX halo thickness 3.7 0.3-42.8 0.297 
Mean AX halo thickness 2.5 0.3-19.4 0.381 
 
AX: axillary artery; CI: confidence interval; GCA: giant cell arteritis; IMT: intima-media thickness; OR: odds ratio, TA:
temporal artery 
*Cut-offs for common superficial temporal arteries, frontal and parietal branches, and axillary arteries of 0.42, 0.34, 0.29, and 
1.0mm, respectively [24] 
 
In bold the statistically significant values (p<0.05) 
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values for intima-media thickness (IMT) of TA and AX, defined by Schafer et al., were 
applied, the number of patients with halo without a diagnosis of GCA reduced to 
19/119 (16%); there was also a reduction in the number of patients with halo and GCA 
to 107/224 (47.8%) (Supplementary Table 1). In addition, with this adjustment based 
on the IMT cut-off measurements, the OR for GCA diagnosis increased from 3.3 (95% 
CI:2.0-5.3) to 4.6 (95% CI:2.7-8.1) (Table 3).  
The maximum TA halo thickness and mean TA halo thickness were higher in patients 
who were given a final diagnosis of GCA vs. patients who were not considered to have 
GCA (0.81±0.44 vs. 0.47±0.33 and 0.70±0.35 vs. 0.48±0.31; p=<0.001 and p=<0.001 
respectively); however, this difference was not observed in the AX halo thickness 
(Supplementary Table 1). The OR for having a diagnosis of GCA increased with the 
number of segments involved (Table 3); all patients with ≥8 segments containing a 
halo had a diagnosis of GCA. Bilateral TA or AX halos were found less frequently in 
patients without a final diagnosis of GCA in comparison to patients diagnosed with 
GCA (12/119 [10.1%] vs. 72/226 [31.9%]; p<0.001), and the presence of AX halo in 
addition to TA halo increased the OR for diagnosing GCA from 2.4 (95% CI:1.4-3.9) to 
3.1 (95% CI:1.2-8.3).  
Besides the presence of halo, other ultrasound abnormalities were described 
(stenosis, occlusion, and arteriosclerosis). However, none of these ultrasound findings 
was found to be statistically significant as a risk factor for a final diagnosis of GCA 
(Table 3; Supplementary Table 1).  
 
 
3) Effect of glucocorticoid therapy on early ultrasound halo findings 
To determine the association between halo size and the number of days of GC 
treatment, we performed a cross-sectional analysis of all patients with GCA who had 
a halo sign on ultrasound (n=121). A total of 120/121 patients were started on ≥ 40 
mg of prednisolone or equivalent per day; only one patient who underwent 
ultrasound on day 2 of treatment was started on an inferior dose of 30 mg of 
prednisolone. Most patients were scanned within the first 2-days of starting GC 
treatment (71.9%).  
The linear regression model for the TA halos, using the maximum TA halo intima-
media thickness (IMT) registered per patient with GCA (n=112; Graphic 1A), or the 
IMT of all TA halos reported in patients with GCA (n=395; Graphic 1B) showed a 
consistently smaller halo size over the 7-days of GC treatment (r=-0.30, p=0.001, and 
r=-0.23, p<0.001; respectively). The multiple comparisons in ANOVA confirmed a 
statistically significant difference in halo size between baseline and ≥4 days of GC 
treatment (p=0.003) for the maximum TA halo IMT per patient with GCA (n=112; 
Supplementary Graphic 2A). When all TA halos of patients with GCA were considered, 
the multiple comparisons in ANOVA also showed a statistically significant difference 
in halo size between baseline and ≥4 days of GC treatment (p=<0.001) and additionally 
between day 1 and ≥4 days of GC treatment (p=0.041) (n=395; Supplementary 
Graphic 2B). The trend of finding a smaller halo over time was not possible to predict 
after 4 days of GC treatment.
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Graphic 1. Scatter-plots with variation of TA halo thickness according to number of days on GC treatment 
 
 



























































Days of GC treatment 
N=395 TA halos 

















Days of GC treatment 
*Patients with GCA who had at least one measurement of IMT for TA halo reported 
Day 0 represents the patients who haven’t started GC or started GC on that same day; r: Pearson´s regression coefficient 




Regarding the AX halos, when applying linear regression models using the maximum 
AX halo IMT registered per patient with GCA (n=33; Supplementary Graphic 3A), or 
the IMT of all AX halos reported in patients with GCA (n=48; Supplementary Graphic 
3B) the correlation coefficients were very weak and not statistically significant (r=-
0.064, p=0.721, and r=-0.044, p=0.764; respectively). These results were also 
confirmed by the ANOVA analyses in which no statistically significant change in halo 




4) Predictive value of halo for clinical outcome at 2-weeks and 6-month 
The differences between presence vs. absence of halo on ultrasound and clinical 
features at 2-weeks and 6-months in patients with GCA were assessed (Table 4). At 2-
weeks, patients with halo reported less new constitutional symptoms since disease 
presentation (2.5% vs. 9.5%; p=0.023) and had higher mean levels of ESR (14.8±12.3 
vs. 11.4±11.7; p=0.001). No differences were found in the occurrence of new visual 
symptoms at 2-weeks and 6-months; however, patients with halo were reported to 
have more new and maintained visual symptoms (31.4% vs. 17.1%, p=0.013, and 
34.7% vs. 16.2%, p=0.002). 
 
 
Table 4: Comparison between the presence vs. absence of halo and clinical features 
at 2-weeks and 6-months 
 
 
Presence of halo 
on ultrasound 
(n= 121) 




Disease symptoms at 2-weeks (new), n (%) 
Constitutional symptoms (any) 3 (2.5) 10 (9.5) 0.023 
Fatigue  3 (2.5) 4 (3.8) 0.565 
Anorexia 0 (0.0) 3 (2.9) 0.061 
Fever or night sweats 0 (0.0) 4 (3.8) 0.030 
PMR features (any) 0 (0.0) 2 (1.9) 0.127 
Bilateral shoulder pain 0 (0.0) 1 (1.0) 0.282 
Early morning stiffness 0 (0.0) 0 (0.0)  
Bilateral hip stiffness 0 (0.0) 1 (1.0) 0.282 
Localised pain in the head 0 (0.0) 2 (1.9) 0.127 
Generalised scalp tenderness 0 (0.0) 2 (1.9) 0.127 
Jaw claudication 1 (0.8) 1 (1.0) 0.920 
Tongue claudication 1 (0.8) 0 (0.0) 0.351 
Visual symptoms (any) 1 (0.8) 4 (3.8) 0.128 
Reduced or lost vision 0 (0.0) 2 (1.9) 0.127 
Double vision 0 (0.0) 0 (0.0)  
Amaurosis fugax 1 (0.8) 2 (1.9) 0.480 
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Disease symptoms at 2-weeks (new and maintained), n (%) 
Constitutional symptoms (any) 43 (35.5) 46 (43.8) 0.201 
Fatigue  37 (30.6) 38 (36.2) 0.372 
Anorexia 10 (8.3) 15 (14.3) 0.150 
Fever or night sweats 15 (12.4) 15 (14.3) 0.676 
PMR features (any) 10 (8.3) 13 (12.4) 0.307 
Bilateral shoulder pain 8 (6.6) 10 (9.5) 0.420 
Early morning stiffness 6 (5.0) 1 (1.0) 0.083 
Bilateral hip stiffness 4 (3.3) 3 (2.9) 0.846 
Localised pain in the head 30 (24.8) 38 (36.2) 0.062 
Generalised scalp tenderness 13 (10.7) 19 (18.1) 0.114 
Jaw claudication 24 (19.8) 19 (18.1) 0.740 
Tongue claudication 4 (3.3) 1 (1.0) 0.230 
Visual symptoms (any) 38 (31.4) 18 (17.1) 0.013 
Reduced or lost vision 36 (29.8) 17 (16.2) 0.016 
Double vision 2 (1.7) 0 (0.0) 0.186 
Amaurosis fugax 2 (1.7) 2 (1.9) 0.886 
Follow up assessments at 2-weeks 
ESR (mm/hr); mean (SD) 14.8±12.3 11.4±11.7 0.001 
CRP (mg/L); mean (SD) 5.4±15.9 3.7±8.1 0.846 
Disease symptoms at 6-months (new), n (%) 
Constitutional symptoms  18 (14.9) 11 (10.5) 0.324 
Fatigue  12 (9.9) 8 (7.6) 0.544 
Anorexia 3 (2.5) 3 (2.9) 0.860 
Fever or night sweats 5 (4.1) 5 (4.8) 0.818 
PMR features 7 (5.8) 7 (6.7) 0.784 
Bilateral shoulder pain 4 (3.3) 6 (5.7) 0.380 
Early morning stiffness 3 (2.5) 4 (3.8) 0.565 
Bilateral hip stiffness 4 (3.3) 4 (3.8) 0.838 
Localised pain in the head 5 (4.1) 8 (7.6) 0.262 
Generalised scalp tenderness 2 (1.7) 5 (4.8) 0.178 
Jaw claudication 1 (0.8) 3 (2.9) 0.248 
Tongue claudication 2 (1.7) 0 (0.0) 0.186 
Visual symptoms 5 (4.1) 4 (3.8) 0.902 
Reduced or lost vision 5 (4.1) 1 (1) 0.138 
Double vision 1 (0.8) 3 (2.9) 0.248 
Amaurosis fugax 0 (0.0) 2 (1.9) 0.127 
Disease symptoms at 6-months (new and maintained), n (%) 
Constitutional symptoms (any) 44 (36.4) 42 (40.0) 0.574 
Fatigue  36 (29.8) 39 (37.1) 0.239 
Anorexia 7 (5.8) 11 (10.5) 0.194 
Fever or night sweats 14 (11.6) 13 (12.4) 0.851 
PMR features (any) 12 (9.9) 12 (11.4) 0.713 
Bilateral shoulder pain 9 (7.4) 11 (10.5) 0.423 
Early morning stiffness 6 (5.0) 4 (3.8) 0.675 
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Bilateral hip stiffness 5 (4.1) 6 (5.7) 0.581 
Localised pain in the head 19 (15.7) 32 (30.5) 0.008 
Generalised scalp tenderness 9 (7.4) 10 (9.5) 0.573 
Jaw claudication 10 (8.3) 11 (10.5) 0.568 
Tongue claudication 3 (2.5) 1 (1.0) 0.385 
Visual symptoms (any) 42 (34.7) 17 (16.2) 0.002 
Reduced or lost vision 40 (33.1) 15 (14.3) 0.001 
Double vision 3 (2.5) 3 (2.9) 0.860 
Amaurosis fugax 2 (1.7) 2 (1.9) 0.886 
Follow up assessments at 6-months 
VDI; mean (SD) 0.57±0.965 0.47±0.735 0.706 
ESR (mm/hr); mean (SD) 16.0±13.8 16.1±17.3 0.333 
CRP (mg/L); mean (SD) 7.6±15.8 6.0±12.0 0.824 
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PMR: polymyalgia rheumatica; SD: standard 
deviation; TAB: temporal artery biopsy; VDI: Vasculitis Damage Index 
 
*Pearson's Chi-squared test, student's independent t-test or the Mann-Whitney U test 





The inclusion of ultrasound in the diagnostic assessment of GCA has been an 
increasing reality for many centres treating this disease, particularly in the last decade. 
In this present sub-analysis of the TABUL study [9], the halo sign, deemed as the most 
important ultrasound finding to diagnose GCA [16], was only found in 121/226 (53.5%) 
of patients who were given a final diagnosis of GCA by the treating physician after full 
disclosure of the TAB and ultrasound results. This low percentage could be explained 
by several reasons: 1) When the TABUL study was conducted (2010-2013) the majority 
of sonographers had little or no experience with vascular ultrasound [9,26] which 
might have influenced the quality of the ultrasound results, even after a strict training 
program had been undertaken (see methods); 2) The TABUL study allowed the use of 
probes with a B-mode frequency of 10 MHz, which is currently considered an 
insufficient resolution for TA assessment [17]; 3) The presence of vessel occlusion 
caused by vasculitis might have precluded the correct identification of halo sign by 
less experienced sonographers; 4) In the majority of studies, the presence of a halo 
sign on ultrasound has shown higher specificity than sensitivity to diagnose GCA [10–
14]; therefore, in a disease that carries a high risk of ischaemic complications if left 
untreated, physicians are likely to be less prepared to exclude GCA based on a 
negative ultrasound, than to diagnose this disease based on a positive examination 
and suggestive clinical presentation; 5) At the time the TABUL study was conducted, 
only few centres regularly used this imaging technique and ultrasound was still not 
part of the EULAR recommendations [17,34] to diagnose GCA, thus many physicians 
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might have had little reliance on ultrasound results to exclude GCA; 6) Possible false 
clinical diagnosis of GCA, supported by the low positive TABs (31.6%) reported in 
patients with GCA and absence of halo on ultrasound. 
We found that the presence of halo sign was associated with the most specific findings 
of GCA such as positive TAB (p<0.001), jaw claudication (p=0.018) and visual 
symptoms (p=0.003), but not with constitutional symptoms (p=0.373), PMR (p=0.054) 
or headache (p=0.102) which are more frequent in GCA but have little specificity for 
this diagnosis. In addition, physical examination findings were significantly associated 
with the presence of ipsilateral halo, contrasting with the previous work by Schmidt 
et al. in which ophthalmic complications were not significantly related to positive 
temporal artery ultrasound [30]. 
When looking specifically at the type of ultrasound findings and their relation to final 
diagnosis of GCA, only the presence of halo sign contributed to the diagnosis. The 
presence or absence of stenosis or occlusion were not discriminatory.  In addition, 
bilateral halos, TA halo with AX halo, adjusted IMT cut-offs for TA and AX halos, and 
more arterial segments with halo increased the odds ratio for having the diagnosis of 
GCA. These findings suggest that a potential composite score including these halo 
abnormalities, instead of the current binary presence / absence of halo in any arterial 
segment assessed, might improve the probability of correctly diagnosing GCA in 
patients with clinical features suggestive of GCA [35,36]. Moreover, it confirms that 
additional ultrasound assessment of stenosis or occlusion is no longer necessary to 
support the diagnosis of GCA [37]. 
In the cross-sectional analysis of all patients with GCA who had a halo sign on 
ultrasound we observed a significantly smaller TA halo size during the 7-day period 
from commencing high doses of GCs. This was demonstrated by looking at the 
maximum TA halo size per patient (r=-0.30, p=0.001) or by considering all TA halos 
reported (r=-0.23, p<0.001). Although in both cases the negative correlation was 
weak, when performing an ANOVA analysis, we observed significantly smaller halos 
between baseline and ≥ 4 days of GC treatment. Therefore, these findings support the 
use of TA ultrasound as a potential surrogate marker for disease activity and response 
to GCs, even in the early stages of treatment (≤ 7 days). In addition, our current data 
(albeit limited by its cross-sectional design) establishes the rationale for undertaking 
prospective monitoring studies using ultrasound as a biomarker. We anticipate this 
will be particularly useful in the future for patients treated with IL-6 inhibitors [34,38] 
because they will limit the usefulness of CRP and ESR to monitor activity. In addition, 
our data corroborates the need for rapid diagnostic assessment in GCA, because prior 
to or in the first few days of GC treatment, the TA halo size is larger and therefore is 
more visible upon ultrasound examination and less likely to be missed by the 
sonographers. This fact could explain the decrease in sensitivity with treatment 
observed by Hauenstein and colleagues [39], using ultrasound, that ranged from 88% 
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in the first day of GCs to 50% following >4 days of GCs. For patients with large-vessel 
(LV) involvement of the disease (LV-GCA), the cross-sectional analysis of the AX halos 
showed no correlation between halo size and number of days on GCs in the first 7 
days of treatment, which could be explained by the fact that in larger arteries the halo 
sign takes much longer time to disappear [31,40] and therefore a week would not be 
enough to see a significant variation. However, only a small proportion of patients 
with GCA and halo sign had at least one axillary halo (27.2%). Prospective studies with 
longer duration and in individual patients are warranted to assess the long-term 
relation of halo sign thickness with features of GCA. 
When looking at the potential predictive role of the presence of halo at baseline with 
the occurrence of new ischaemic events at 2-weeks and 6-months, no association was 
found. Nevertheless, when evaluating the presence of new or maintained symptoms, 
patients with halo sign at baseline had more visual symptoms at 2-weeks and 6-
months, reflecting the irreversible nature of eye involvement in this disease. This 
predictive assessment is however limited by the lack of follow-up data after 6-months. 
In summary, we conclude that in newly diagnosed GCA, if a halo sign is detected, its 
presence is associated with manifestations of ischaemic symptoms and abnormal 
findings at examination of the ispilateral side. Furthermore, its size is affected by the 
duration of GC treatment. These findings encourage the early use of the halo sign as 
a biomarker of response to treatment and enhance its potential prognostic role for 
the presence of irreversible ischaemic features of the disease (e.g. vision loss). 
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Supplementary Figure S1. Presenting symptoms and physical examination of patients 
with the diagnosis of giant cell arteritis  
 
 
AX: axillary arteries; PMR: polymyalgia rheumatica; TA: temporal arteries 
* Constitutional symptoms - fatigue, anorexia, fever or night sweats 
**Visual symptoms - reduced or lost vision in either eye, double vision, or amaurosis fugax 
** PMR features - new onset of bilateral shoulder pain, early morning stiffness or hip stiffness or pain 
§Eye abnormality - anterior ischaemic optic neuropathy, posterior ischaemic optic neuropathy, relative afferent 
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 Diagnosis of GCA  
(N=226) 
No diagnosis of 
GCA (N=119) 
p-value* 
Ultrasound findings - N/N of patients (%) 
Presence of halo sign 121/226 (53.5) 31/119 (26.1) <0.001 
TA halo  114/226 (50.4) 30/119 (25.2) <0.001 
AX halo 34/226 (15.0) 6/119 (5.0) 0.006 
Presence of stenosis 24/114 (21.1) 6/34 (17.6) 0.665 
TA stenosis 24/111 (21.6) 8/36 (22.2) 0.940 
AX stenosis 6/33 (18.2) 1/10 (10.0) 0.539 
Presence of occlusion 26/120 (21.7) 4/37 (10.8) 0.142 
TA occlusion 26/116 (22.4) 4/34 (11.8) 0.172 
AX occlusion 0/32 (0) 1/10 (10) 0.070 
Presence of arteriosclerosis 49/117 (41.9) 14/38 (36.8) 0.583 
TA arteriosclerosis 43/109 (39.4) 11/34 (32.4) 0.456 
AX arteriosclerosis 10/34 (29.4) 4/11 (36.4) 0.665 
Halo general characteristics - N/N of patients (%) 
Halo sign with adjusted IMT cut-offs (TA or AX) ** 107/224 (47.8) 19/119 (16.0) <0.001 
TA halo with adjusted IMT cut-offs ** 101/224 (45.0) 17/118 (14.4) <0.001 
AX halo with adjusted IMT cut-offs ** 21/225 (9.3) 3/119 (2.5) 0.013 
Bilateral halo (TA or AX) 72/226 (31.9) 12/119 (10.1) <0.001 
Bilateral TA halo  67/226 (29.6) 12/119 (10.1) <0.001 
Bilateral AX halo 15/226 (5.8) 2/119 (1.7) 0.043 
TA halo without AX halo 87/226 (38.5) 25/119 (21.0) 0.001 
TA halo with AX halo 27/226 (11.9) 5/119 (4.2) 0.018 
Number of arterial segments with the presence of halo - N/N of patients (%) 
≥ 1 arterial segments 121/226 (53.5) 31/119 (26.1) <0.001 
≥ 2 arterial segments 93/226 (41.2) 19/119 (16.0) <0.001 
≥ 3 arterial segments 67/226 (29.6) 7/119 (5.9) <0.001 
≥ 4 arterial segments 54/226 (23.9) 4/119 (3.4) <0.001 
≥ 5 arterial segments 37/226 (16.4) 3/119 (2.5) <0.001 
≥ 6 arterial segments 33/226 (14.6) 2/119 (1.7) <0.001 
≥ 7 arterial segments 25/226 (11.1) 1/119 (0.8) 0.001 
≥ 8 arterial segments 17/226 (7.5) 0/119 (0) 0.002 
10 arterial segments 3/226 (1.3) 0/119 (0) 0.207 
Halo thickness - mean (SD) 
Maximum TA halo thickness (141 patients) 0.81±0.44 0.47±0.33 <0.001 
Mean TA halo thickness (452 TA halos) 0.70±0.35 0.48±0.31 <0.001 
Maximum AX halo thickness (39 patients) 1.39±1.02 1.05±0.37 0.290 
Mean AX halo thickness (56 AX halos) 1.35±1.03 1.05±0.34 0.371 
AX: axillary artery; GCA: giant cell arteritis; IMT: intima-media thickness; TA: temporal artery 
 
*Pearson's Chi-squared test, student's independent t-test or the Mann-Whitney U test; in bold the statistically significant values (p<0.05) 




Supplementary Figure S2. Boxplot-graphics with of TA halo thickness according to the number of days on GC treatment  
 





















ANOVA model: p=0.006 between groups 
 
With the removal of outlier n19 no relevant change was seen in the performance 
characteristics of the model  
 





















ANOVA model: p<0.001 between groups 
 
With the removal of outlier n61 no relevant change was seen in the performance characteristics 
of the model  
 
Day 0 represents the patients who haven’t started GC or started GC on that same day.  
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Supplementary Figure S3. Scattered-plots with variation of AX halo thickness according to number of days on GC treatment 
 
 




























B. Halo thickness of all AX segments from patients with GCA 
 
With the removal of the outliers from day 3 no relevant changes were seen in the performance characteristics of the model 
* Patients with GCA who had at least one measurement of IMT for AX halo reported 
 
Day 0 represents the patients who haven’t started GC or started GC on that same day; r: Pearson´s regression coefficient  




















































Days of GC treatment 
N=48 AX halos 
 
r=-0.044, p=0.764 
